Evaluation of cost and survival in intracranial gliomas using the Value Driven Outcomes database: a retrospective cohort analysis

View More View Less
  • 1 Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah;
  • 2 Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; and
  • 3 Department of Neurosurgery, Hofstra Northwell School of Medicine, Manhasset, New York
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Gliomas occur in 3–4 individuals per 100,000 individuals and are one of the most common primary brain tumors. Treatment options are limited for gliomas despite the progressive nature of the disease. The authors used the Value Driven Outcomes (VDO) database to identify cost drivers and subgroups that are involved in the surgical treatment of gliomas.

METHODS

A retrospective cohort of patients with gliomas treated at the authors’ institution from August 2011 to February 2018 was evaluated using medical records and the VDO database.

RESULTS

A total of 263 patients with intracranial gliomas met the authors’ inclusion criteria and were included in the analysis (WHO grade I: 2.0%; grade II: 18.5%; grade III: 18.1%; and grade IV: 61.4%). Facility costs were the major (64.4%) cost driver followed by supplies (16.2%), pharmacy (10.1%), imaging (4.5%), and laboratory (4.7%). Univariate analysis of cost contributors demonstrated that American Society of Anesthesiologists physical status (p = 0.002), tumor recurrence (p = 0.06), Karnofsky Performance Scale score (p = 0.002), length of stay (LOS) (p = 0.0001), and maximal tumor size (p = 0.03) contributed significantly to the total costs. However, on multivariate analysis, only LOS (p = 0.0001) contributed significantly to total costs. More extensive tumor resection in WHO grade III and IV tumors was associated with significant improvement in survival (p = 0.004 and p = 0.02, respectively).

CONCLUSIONS

Understanding care costs is challenging because of the highly complex, fragmented, and variable nature of healthcare delivery. Adopting effective strategies that would reduce facility costs and limit LOS is likely the most important aspect in reducing intracranial glioma treatment costs.

ABBREVIATIONS ASA = American Society of Anesthesiologists; EOR = extent of resection; GBM = glioblastoma; iMRI = intraoperative MRI; KPS = Karnofsky Performance Scale; LOS = length of stay; VDO = Value Driven Outcomes; 5-ALA = 5-aminolevulinic acid.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Randy L. Jensen: Clinical Neurosciences Center, University of Utah, Salt Lake City, UT. neuropub@hsc.utah.edu.

INCLUDE WHEN CITING Published online March 29, 2019; DOI: 10.3171/2018.12.JNS183109.

H.W. and M.A.A. contributed equally to this work.

Disclosures Dr. Jensen reports being a consultant for Medtronic.

  • 1

    Alternative Payment Model Framework and Progress Tracking (APM FPT) Work Group: Alternative Payment Model (APM) Framework: Final White Paper, 2016. Health Care Payment Learning & Action Network (https://hcp-lan.org/workproducts/apm-whitepaper.pdf)[Accessed January 16, 2019]

    • Search Google Scholar
    • Export Citation
  • 2

    Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X: The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:11291136, 2016

    • Search Google Scholar
    • Export Citation
  • 3

    Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, : Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:13441355, 2016

    • Search Google Scholar
    • Export Citation
  • 4

    Butenschön VM, Ille S, Sollmann N, Meyer B, Krieg SM: Cost-effectiveness of preoperative motor mapping with navigated transcranial magnetic brain stimulation in patients with high-grade glioma. Neurosurg Focus 44(6):E18, 2018

    • Search Google Scholar
    • Export Citation
  • 5

    DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, : Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol 19:16401650, 2017

    • Search Google Scholar
    • Export Citation
  • 6

    Eljamel MS, Mahboob SO: The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI. Photodiagn Photodyn Ther 16:3543, 2016

    • Search Google Scholar
    • Export Citation
  • 7

    Eseonu CI, Rincon-Torroella J, ReFaey K, Quiñones-Hinojosa A: The cost of brain surgery: awake vs asleep craniotomy for perirolandic region tumors. Neurosurgery 81:307314, 2017

    • Search Google Scholar
    • Export Citation
  • 8

    Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, : Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519527, 2007

    • Search Google Scholar
    • Export Citation
  • 9

    Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:22622266, 2003

    • Search Google Scholar
    • Export Citation
  • 10

    Guan J, Karsy M, Bisson EF, Couldwell WT: Patient-level factors influencing hospital costs and short-term patient-reported outcomes after transsphenoidal resection of sellar tumors. Neurosurgery 83:726731, 2018

    • Search Google Scholar
    • Export Citation
  • 11

    Henaine AM, Paubel N, Ducray F, Diebold G, Frappaz D, Guyotat J, : Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther 41:47–53, 2016

    • Search Google Scholar
    • Export Citation
  • 12

    Institute of Medicine Committee on the Learning Health Care System in America: Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press, 2013

    • Search Google Scholar
    • Export Citation
  • 13

    Jiang S, Hill K, Patel D, Waldeck AR, Botteman M, Aly A, : Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients. J Med Econ 20:12371243, 2017

    • Search Google Scholar
    • Export Citation
  • 14

    Karsy M, Brock AA, Guan J, Bisson EF, Couldwell WT: Assessment of cost drivers in transsphenoidal approaches for resection of pituitary tumors using the Value-Driven Outcome Database. World Neurosurg 105:818823, 2017

    • Search Google Scholar
    • Export Citation
  • 15

    Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H: Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 12:10621070, 2011

    • Search Google Scholar
    • Export Citation
  • 16

    Latif AZ, Signorini D, Gregor A, Whittle IR: The costs of managing patients with malignant glioma at a neuro-oncology clinic. Br J Neurosurg 12:118122, 1998

    • Search Google Scholar
    • Export Citation
  • 17

    McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, : Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63:700708, 2008

    • Search Google Scholar
    • Export Citation
  • 18

    Mendez I, Jacobs P, MacDougall A, Schultz M: Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci 28:6165, 2001

    • Search Google Scholar
    • Export Citation
  • 19

    Messali A, Villacorta R, Hay JW: A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics 32:12011212, 2014

    • Search Google Scholar
    • Export Citation
  • 20

    Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, : CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 19 (Suppl 5):v1v88, 2017

    • Search Google Scholar
    • Export Citation
  • 21

    Patterson H: Nobody Can Afford a Brain Tumor. The Financial Impacts of Brain Tumors on Patients and Families: A Summary of Findings. San Francisco: National Brain Tumor Foundation, 2007

    • Search Google Scholar
    • Export Citation
  • 22

    Pickard JD, Bailey S, Sanderson H, Rees M, Garfield JS: Steps towards cost-benefit analysis of regional neurosurgical care. BMJ 301:629635, 1990

    • Search Google Scholar
    • Export Citation
  • 23

    Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, : Economics of malignant gliomas: a critical review. J Oncol Pract 11:e59e65, 2015

    • Search Google Scholar
    • Export Citation
  • 24

    Ray S, Bonafede MM, Mohile NA: Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits 7:140149, 2014

    • Search Google Scholar
    • Export Citation
  • 25

    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, : Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:15831588, 2004

    • Search Google Scholar
    • Export Citation
  • 26

    Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110:1324, 2007

    • Search Google Scholar
    • Export Citation
  • 27

    Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V: Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:9971003, 2011

    • Search Google Scholar
    • Export Citation
  • 28

    Senft C, Seifert V, Hermann E, Franz K, Gasser T: Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 63 (4 Suppl 2):257267, 2008

    • Search Google Scholar
    • Export Citation
  • 29

    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, : Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:13381345, 2008

    • Search Google Scholar
    • Export Citation
  • 30

    Spetzler RF, Kick SA: The status of neurosurgery in the United States: 2010 and beyond. World Neurosurg 74:3240, 2010

  • 31

    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459466, 2009

    • Search Google Scholar
    • Export Citation
  • 32

    Undabeitia J, Torres-Bayona S, Samprón N, Arrázola M, Bollar A, Armendariz M, : Indirect costs associated with glioblastoma: experience at one hospital. Neurologia 33:8591, 2018

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 285 285 41
Full Text Views 55 55 2
PDF Downloads 94 94 2
EPUB Downloads 0 0 0